Table 3.

Summary of combination microbicide studies and their results

Combination		Study type	CI range (HIV tropism)a	Effectb	Reference
Compound A	Compound B
CAP	sCD4	In vitro	0.29–0.79 (X4)	+	87
			0.40–0.52 (R5)	+
CAP	UC781	In vitro	0.12–0.23 (X4)c	+	7
			0.39–0.52 (X4)d	+
CAP	EFV	In vitro	0.14–0.30 (X4)	+	7
CAP	AZT	In vitro	0.22–0.30 (X4)	+	7
PRO 2000	IgGb12	In vitro	0.69–1.38 (X4)	+/−	40
			0.50–0.59 (R5)c	+
			0.61–1.58 (R5)d	+/−
PRO 2000	T-20	In vitro	0.47–0.98 (X4)	+	40
			0.46–1.26 (R5)	+/∼
PRO 2000	TAK779	In vitro	0.26–0.52 (R5)c	+	40
			0.20–0.69 (R5)d	+
PRO 2000	Cyanovirin-N	In vitro	1.56–2.00 (X4)	−	40
			0.10–1.11 (R5)	+/∼
Carrageenan	MIV-150	In vitro	0.90–1.16 (X4)	∼	36
alt-PSMA	PSS	In vitro	0.20–1.12 (X4)	+/∼	Pirrone et al., unpublished data
alt-PSMA	Cyanovirin-N	In vitro	0.17–0.34 (X4)	+	Pirrone et al., unpublished data
alt-PSMA	EFV	In vitro	0.90–1.30 (X4)	∼	Pirrone et al., unpublished data

^aCI calculated using CalcuSyn. NA, CI not available.

^bCombined activities were assessed as follows: +, synergistic; ∼, additive; −, antagonistic.

^cIn a cell line.

^dIn PBMCs.